As announced on December 8, 2020, the voluntary suspension of trading and subsequent delisting of PDL’s common stock (Nasdaq: PDLI) occurred prior to market opening on December 31, 2020. The Company’s transfer books closed as of the filing of the certificate of dissolution on January 4, 2021 (the “Final Record Date”).

PDL BioPharma (known as Protein Design Labs prior to 2006) is a publicly traded American holding company that since 2008 manages patents and other intellectual property that had been generated by the company. [2][3] In 2008 in response to shareholder pressure, PDL spun out its active development programs to a company called Facet Biotech that it...

For Investor updates on the PDL Biopharma dissolution process, please sign up here.

• Give students the tools to develop a nuanced understanding of peacebuilding—particularly within the Israeli-Palestinian conflict--by connecting high-level strategic dialogue with realities on the ground. • Foster civil-military relationships, understanding, and dialogue.

Track PDL BioPharma, Inc. (PDLI) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors.

Jun 1, 2015 · PDL BioPharma, Inc. is a biotech company engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with...

Dec 30, 2020 · Get the latest PDL BioPharma, Inc PDLI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Feb 22, 2017 · Find the latest PDL BioPharma, Inc., PDLI stock market data. Get a full understanding of how PDL BioPharma, Inc. is performing with stock quotes and prices, as well as real-time news and...

Real-time prices are provided by Cboe BZX Exchange on individual U.S. equities quote pages. During market hours, the real-time Cboe BZX price displays and new trade updates are …

PDL BioPharma, Inc. manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology...